摘要

Mutations in epidermal growth factor receptor (EGFR) commonly occur in non-small‑cell lung cancer (NSCLC) patients characterized by female gender, never‑smoker status and adenocarcinoma histology. The aim of this study was to determine whether gender is a confounding factor for EGFR mutations in NSCLC. To elucidate the confounding effect, Pearson's χ2 test and logistic regression models were used to correlate these characteristics with EGFR mutations in 426 NSCLC patients treated at our institutes. Of those 426 NSCLC patients, 47% were females, 57% were non-smokers and 84% had adenocarcinomas. The multivariate logistic regression analysis demonstrated that never-smoker status [odds ratio (OR)=3.49, 95% confidence interval (CI): 1.99-6.13; P<0.001)] and adenocarcinoma (OR=9.43, 95% CI 3.62-24.56; P<0.001) were associated with EGFR mutations; however, gender was not (OR=1.25, 95% CI: 0.73-2.15; P=0.416). Furthermore, gender was not associated with EGFR mutation subtypes (OR=1.19, 95% CI: 0.56-2.50; P=0.650). The frequency of EGFR mutations among females and males was not different in non-smokers (64.8 vs. 55.8%, P=0.204) or ever‑smokers (27.8 vs. 24.2%, P=0.775). Therefore, if the assessment for EGFR mutation status was limited to non‑smoking females with adenocarcinoma, up to 40% of the patients harboring EGFR mutations would be precluded from the benefit of EGFR inhibitor therapy. Our results indicated that gender is a confounding factor for EGFR mutations in NSCLC and suggested that gender may not be associated with tumorigenesis in NSCLC‑harboring EGFR mutations.
原文英語
頁(從 - 到)252-258
頁數7
期刊Molecular and Clinical Oncology
2
出版狀態已發佈 - 十二月 23 2013

指紋

Epidermal Growth Factor Receptor
Lung Neoplasms
Smoking
Mutation
Adenocarcinoma
Odds Ratio
Confidence Intervals
Logistic Models
Histology
Carcinogenesis
Regression Analysis

引用此文

@article{79568c018d224408a2e307f8508a2c97,
title = "Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small‑cell lung cancer",
abstract = "Mutations in epidermal growth factor receptor (EGFR) commonly occur in non-small‑cell lung cancer (NSCLC) patients characterized by female gender, never‑smoker status and adenocarcinoma histology. The aim of this study was to determine whether gender is a confounding factor for EGFR mutations in NSCLC. To elucidate the confounding effect, Pearson's χ2 test and logistic regression models were used to correlate these characteristics with EGFR mutations in 426 NSCLC patients treated at our institutes. Of those 426 NSCLC patients, 47{\%} were females, 57{\%} were non-smokers and 84{\%} had adenocarcinomas. The multivariate logistic regression analysis demonstrated that never-smoker status [odds ratio (OR)=3.49, 95{\%} confidence interval (CI): 1.99-6.13; P<0.001)] and adenocarcinoma (OR=9.43, 95{\%} CI 3.62-24.56; P<0.001) were associated with EGFR mutations; however, gender was not (OR=1.25, 95{\%} CI: 0.73-2.15; P=0.416). Furthermore, gender was not associated with EGFR mutation subtypes (OR=1.19, 95{\%} CI: 0.56-2.50; P=0.650). The frequency of EGFR mutations among females and males was not different in non-smokers (64.8 vs. 55.8{\%}, P=0.204) or ever‑smokers (27.8 vs. 24.2{\%}, P=0.775). Therefore, if the assessment for EGFR mutation status was limited to non‑smoking females with adenocarcinoma, up to 40{\%} of the patients harboring EGFR mutations would be precluded from the benefit of EGFR inhibitor therapy. Our results indicated that gender is a confounding factor for EGFR mutations in NSCLC and suggested that gender may not be associated with tumorigenesis in NSCLC‑harboring EGFR mutations.",
author = "Hsiao, {Shin Hsin} and Sey-En Lin and Chou, {Yu Ting} and Jinn-Li Wang and Chi-Li Chung and Ming-Chih Yu and Chia-Lang Fang and Lee, {Hsin Lun} and Ling-Ling Chiang and Hsingjin-Eugene Liu and Wu, {Cheng Wen}",
year = "2013",
month = "12",
day = "23",
language = "English",
volume = "2",
pages = "252--258",
journal = "Molecular and Clinical Oncology",
issn = "2049-9450",
publisher = "Spandidos Publications",

}

TY - JOUR

T1 - Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small‑cell lung cancer

AU - Hsiao, Shin Hsin

AU - Lin, Sey-En

AU - Chou, Yu Ting

AU - Wang, Jinn-Li

AU - Chung, Chi-Li

AU - Yu, Ming-Chih

AU - Fang, Chia-Lang

AU - Lee, Hsin Lun

AU - Chiang, Ling-Ling

AU - Liu, Hsingjin-Eugene

AU - Wu, Cheng Wen

PY - 2013/12/23

Y1 - 2013/12/23

N2 - Mutations in epidermal growth factor receptor (EGFR) commonly occur in non-small‑cell lung cancer (NSCLC) patients characterized by female gender, never‑smoker status and adenocarcinoma histology. The aim of this study was to determine whether gender is a confounding factor for EGFR mutations in NSCLC. To elucidate the confounding effect, Pearson's χ2 test and logistic regression models were used to correlate these characteristics with EGFR mutations in 426 NSCLC patients treated at our institutes. Of those 426 NSCLC patients, 47% were females, 57% were non-smokers and 84% had adenocarcinomas. The multivariate logistic regression analysis demonstrated that never-smoker status [odds ratio (OR)=3.49, 95% confidence interval (CI): 1.99-6.13; P<0.001)] and adenocarcinoma (OR=9.43, 95% CI 3.62-24.56; P<0.001) were associated with EGFR mutations; however, gender was not (OR=1.25, 95% CI: 0.73-2.15; P=0.416). Furthermore, gender was not associated with EGFR mutation subtypes (OR=1.19, 95% CI: 0.56-2.50; P=0.650). The frequency of EGFR mutations among females and males was not different in non-smokers (64.8 vs. 55.8%, P=0.204) or ever‑smokers (27.8 vs. 24.2%, P=0.775). Therefore, if the assessment for EGFR mutation status was limited to non‑smoking females with adenocarcinoma, up to 40% of the patients harboring EGFR mutations would be precluded from the benefit of EGFR inhibitor therapy. Our results indicated that gender is a confounding factor for EGFR mutations in NSCLC and suggested that gender may not be associated with tumorigenesis in NSCLC‑harboring EGFR mutations.

AB - Mutations in epidermal growth factor receptor (EGFR) commonly occur in non-small‑cell lung cancer (NSCLC) patients characterized by female gender, never‑smoker status and adenocarcinoma histology. The aim of this study was to determine whether gender is a confounding factor for EGFR mutations in NSCLC. To elucidate the confounding effect, Pearson's χ2 test and logistic regression models were used to correlate these characteristics with EGFR mutations in 426 NSCLC patients treated at our institutes. Of those 426 NSCLC patients, 47% were females, 57% were non-smokers and 84% had adenocarcinomas. The multivariate logistic regression analysis demonstrated that never-smoker status [odds ratio (OR)=3.49, 95% confidence interval (CI): 1.99-6.13; P<0.001)] and adenocarcinoma (OR=9.43, 95% CI 3.62-24.56; P<0.001) were associated with EGFR mutations; however, gender was not (OR=1.25, 95% CI: 0.73-2.15; P=0.416). Furthermore, gender was not associated with EGFR mutation subtypes (OR=1.19, 95% CI: 0.56-2.50; P=0.650). The frequency of EGFR mutations among females and males was not different in non-smokers (64.8 vs. 55.8%, P=0.204) or ever‑smokers (27.8 vs. 24.2%, P=0.775). Therefore, if the assessment for EGFR mutation status was limited to non‑smoking females with adenocarcinoma, up to 40% of the patients harboring EGFR mutations would be precluded from the benefit of EGFR inhibitor therapy. Our results indicated that gender is a confounding factor for EGFR mutations in NSCLC and suggested that gender may not be associated with tumorigenesis in NSCLC‑harboring EGFR mutations.

M3 - Article

VL - 2

SP - 252

EP - 258

JO - Molecular and Clinical Oncology

JF - Molecular and Clinical Oncology

SN - 2049-9450

ER -